Quarterly report
Open the filing on sec.gov
Maze Therapeutics, Inc. (MAZE)
Nasdaq: MAZE · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2024
The companyfiscal 2024, as filed
Revenue$168M
Net income$52.2M
Earnings per share$1.25
Operating cash flow$76.0M
Cash$198M+554.3%
Debtn/a
Shareholders’ equity-$311M+16.8%
Shares, dilutedn/a
Return on equity-36.9%
The recordfrom its filings
Filings in 2026112
Newest filingNov 9 · 10-Q
Annual reportMar 25, 2026
Quarterly reportNov 9, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$25.0M
Insider buys, 12 months$0.00
Patents granted3
Filer categoryNon-accelerated filer<br>Emerging growth company
Trailing twelve months to Sep 2026Net income -$151MCash from operations -$115Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.